Holen Sie sich die Stockscreener-App
469.21
2.04%
-9.75
Handel nachbörslich:
469.26
0.05
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$478.96
Offen:
$480
24-Stunden-Volumen:
1.43M
Relative Volume:
0.64
Marktkapitalisierung:
$174.37B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.88B
KGV:
25.79
EPS:
18.1925
Netto-Cashflow:
$6.75B
1W Leistung:
-0.11%
1M Leistung:
-5.12%
6M Leistung:
-17.30%
1J Leistung:
+11.75%
1-Tages-Spanne:
$468.10
$481.83
1-Wochen-Bereich:
$461.00
$481.83
52-Wochen-Spanne:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
469.21 | 177.99B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
175.15 | 126.66B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.46 | 44.54B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.52 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
307.12 | 30.36B | 3.17B | 642.63M | 516.49M | 10.77 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher Scientific Q1 2026 Financial Results and SEC 10-Q Filing Summary - Minichart
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610 - marketscreener.com
Billionaire Investor Takes New Stake In Thermo Fisher Scientific - Yahoo Finance
Thermo Fisher (NYSE: TMO) grows Q1 revenue and closes $9.1B Clario deal - Stock Titan
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610 - marketscreener.com
Vanguard (NYSE: TMO) reports 28.0M shares of Thermo Fisher, 7.53% stake - Stock Titan
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market Research Report 2026: Opportunities, Trends, Competitive Landscape, Strategies, Forecasts 2020-2035 - GlobeNewswire Inc.
Thermo Fisher Scientific opens bioprocess design center in Massachusetts - chemengonline.com
Soil Testing Equipment Market Size, Share & Growth Outlook - openPR.com
Thermo Fisher Scientific Agrees to Divest Its Microbiology Business to Astorg - ChemAnalyst
PowerFlex thermal cycler boosts PCR flexibility & speed - SelectScience
Molecular Quality Controls Market | THERMO FISHER SCIENTIFIC, INC, Qnostics, Zeptometrix Corporation etc. - openPR.com
Insider Sell: Gianluca Pettiti Sells Shares of Thermo Fisher Sci - GuruFocus
Thermo Fisher Scientific president & COO sells $185,064 in stock By Investing.com - Investing.com UK
Thermo Fisher (NYSE: TMO) COO executes 400-share Rule 10b5-1 sale - Stock Titan
Thermo Fisher Scientific to sell its microbiology business as Astorg - chemengonline.com
Thermo Fisher Scientific launches applied Biosystems PowerFlex Thermal Cycler - Med-Tech Insights
Thermo Fisher Scientific, SHL Medical Collaborate on Integrated Drug-Device Solutions - Medical Product Outsourcing
Do You Believe in The Long-Term Growth Outlook of Thermo Fisher Scientific (TMO)? - Insider Monkey
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies - BioSpace
Thermo Fisher Scientific to Host Investor DayApril 28, 2026 - BioSpace
Thermo Fisher to Sell Microbiology Business to Astorg - WSJ
Thermo Fisher opens Plainville design center amid $2B push for U.S. manufacturing - The Business Journals
Thermo Fisher sells microbiology business for $1B - BioWorld News
Thermo Fisher agrees to sell microbiology business to Astorg in $1bn deal - Medical Device Network
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of - PharmiWeb.com
Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg - MedTech Dive
Thermo Fisher Scientific Opens Flagship U.S. Bioprocess Design Center in MA - Contract Pharma
Thermo Fisher Stock Fell After Q1 2026 Earnings. Is TMO a Buy? - TIKR.com
Medical Refrigerators Market Competitive Analysis to 2028 | - openPR.com
Thermo Fisher drops despite Q1 beat, guidance hike - MSN
Thermo Fisher sells microbiology biz to Astorg for $1.075 B - BioSpectrum Asia
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg - BioSpace
Thermo Fisher to divest microbiology business in $1.07 billion deal with PE firm Astorg - DOTmed
Thermo Fisher sells microbiology business to private equity firm for $1B - The Business Journals
Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion - MSN
Thermo Fisher Scientific Inc (TMO) Stock Price, Trades & News - GuruFocus
Thermo Fisher Scientific (TMO) Sells Microbiology Business for $1.075 Billion - GuruFocus
Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $620 - Moomoo
Morgan Stanley Lowers Price Target on Thermo Fisher Scientific to $620 From $670, Keeps Overweight Rating - marketscreener.com
Thermo Fisher selling microbiology business to Astorg for $1.08B - Yahoo Finance
Astorg III, FCPR, managed by Astorg Asset Management S A.R.L. signed a definitive agreement to acquire Global Microbiology Business from Thermo Fisher Scientific Inc. for approximately $1.1 billion. - marketscreener.com
Latham Advises Astorg in Acquisition of Thermo Fisher Scientific Global Microbiology Business - Latham & Watkins LLP
[144] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan
Thermo Fisher (TMO) Sells Microbiology Business for $1.075 Billi - GuruFocus
Thermo Fisher Buys into Astorg - Baystreet.ca
Luxembourg: Astorg to acquire Thermo Fisher Scientific’s microbiology business for US$1.075bn - Investors in Healthcare
Thermo Fisher to sell microbiology unit to Astorg for $1.08 billion By Investing.com - Investing.com Canada
Thermo Fisher Scientific signs agreement to sell its microbiology business to Astorg - marketscreener.com
Thermo Fisher Scientific to Sell Microbiology Business to Astorg for $1.08 Billion - marketscreener.com
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.12%
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):